We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

10 hedge funds and large institutions have $92.4K invested in Evoke Pharma in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.24% more ownership

Funds ownership: 1.77% → 2.01% (+0.24%)

0% more funds holding

Funds holding: 10 → 10 (0)

5% less capital invested

Capital invested by funds: $97.4K → $92.4K (-$5.01K)

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.42K
2
UBS Group
UBS Group
Switzerland
+$2.19K
3
TRCT
Tower Research Capital (TRC)
New York
+$295
4
Wells Fargo
Wells Fargo
California
+$16

Top Sellers

No sellers this quarter

EVOK Hedge Fund Activity: Q3 2023 in Review

10 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2023, worth a combined $92.4K — down 5.1% from $97.4K a quarter earlier.

Fund positioning in EVOK was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $8.42K.

  • 10 institutional investors held Evoke Pharma (EVOK) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $92.4K of Evoke Pharma stock for Q3 2023, down 5.1% quarter-over-quarter.
  • 0 funds opened new Evoke Pharma positions in Q3 2023 and 0 closed out.
  • The largest Evoke Pharma buyer in Q3 2023 was Geode Capital Management, an estimated $8.42K added.

Based on aggregated 13F filings for Q3 2023.